Prothena Corporation PLC
PRTA6.875USD
+0.065+0.95%
交易中 （美東）報價延遲15分鐘
370.06M總市值
虧損本益比TTM
關於 Prothena Corporation PLC 公司
Prothena Corporation plc 是一家位於愛爾蘭的後期臨牀生物技術公司。該公司從事蛋白質失調研究，並擁有一系列針對罕見外周澱粉樣蛋白疾病的在研治療藥物。該公司正在推進一系列針對各種適應症和靶點的治療候選藥物，以整合有關神經功能障礙和錯誤摺疊蛋白質生物學的科學見解。該公司的藥物包括全資和合作項目，正在開發用於治療 AL 澱粉樣變性、ATTR 澱粉樣變性、阿爾茨海默病、帕金森病和一系列其他神經退行性疾病等疾病的潛在治療方法。其臨牀項目包括用於潛在治療 AL 澱粉樣變性的 birtamimab、用於潛在治療帕金森病的 prasinezumab、用於潛在治療 ATTR 澱粉樣變性的 NNC6019/PRX004 以及用於潛在治療阿爾茨海默病的 PRX005 和 PRX012。
公司簡介
公司代碼PRTA
公司名稱Prothena Corporation PLC
上市日期Dec 21, 2012
CEODr. Gene G. Kinney, Ph.D.
員工數量163
證券類型Ordinary Share
年結日Dec 21
公司地址77 Sir John Rogerson's Quay, Block C
城市DUBLIN
上市交易所NASDAQ Global Select Consolidated
國家Ireland
郵編D02 VK60
電話35312362500
網址https://www.prothena.com/
公司代碼PRTA
上市日期Dec 21, 2012
CEODr. Gene G. Kinney, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Dr. Dennis J. Selkoe, M.D.
Dr. Dennis J. Selkoe, M.D.
Independent Director
Independent Director
4.21K
--
Mr. Richard T. Collier
Mr. Richard T. Collier
Independent Director
Independent Director
1.22K
--
Dr. Lars G. Ekman, M.D., Ph.D.
Dr. Lars G. Ekman, M.D., Ph.D.
Chairman Emeritus
Chairman Emeritus
243.00
--
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
--
--
Ms. Karin L. Walker, CPA
Ms. Karin L. Walker, CPA
Chief Accounting Officer
Chief Accounting Officer
--
--
Ms. Paula K. Cobb
Ms. Paula K. Cobb
Independent Director
Independent Director
--
--
Ms. Helen S. Kim
Ms. Helen S. Kim
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Dr. Dennis J. Selkoe, M.D.
Dr. Dennis J. Selkoe, M.D.
Independent Director
Independent Director
4.21K
--
Mr. Richard T. Collier
Mr. Richard T. Collier
Independent Director
Independent Director
1.22K
--
Dr. Lars G. Ekman, M.D., Ph.D.
Dr. Lars G. Ekman, M.D., Ph.D.
Chairman Emeritus
Chairman Emeritus
243.00
--
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 6月7日 週六
更新時間: 6月7日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
14.75%
Scully (William P)
10.42%
Fennell (Todd W.)
8.53%
T. Rowe Price Associates, Inc.
6.29%
BlackRock Institutional Trust Company, N.A.
6.10%
Other
53.91%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
14.75%
Scully (William P)
10.42%
Fennell (Todd W.)
8.53%
T. Rowe Price Associates, Inc.
6.29%
BlackRock Institutional Trust Company, N.A.
6.10%
Other
53.91%
股東類型
持股股東
佔比
Investment Advisor
41.72%
Individual Investor
18.99%
Hedge Fund
12.64%
Investment Advisor/Hedge Fund
10.92%
Venture Capital
5.48%
Research Firm
2.58%
Bank and Trust
0.65%
Pension Fund
0.21%
Sovereign Wealth Fund
0.11%
Other
6.70%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
457
50.26M
93.38%
-20.92M
2025Q1
472
64.29M
119.45%
-7.39M
2024Q4
479
65.24M
121.19%
+239.99K
2024Q3
476
59.39M
110.43%
-5.39M
2024Q2
479
58.48M
108.76%
-4.67M
2024Q1
472
60.86M
113.29%
-264.94K
2023Q4
474
56.64M
105.77%
-2.21M
2023Q3
476
55.90M
104.65%
-1.73M
2023Q2
475
55.02M
104.46%
-3.12M
2023Q1
464
54.98M
104.68%
-658.88K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
7.94M
14.75%
-129.91K
-1.61%
Mar 31, 2025
Scully (William P)
5.61M
10.42%
-36.34K
-0.64%
Mar 31, 2025
Fennell (Todd W.)
4.59M
8.53%
-54.34K
-1.17%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.38M
6.29%
-232.75K
-6.43%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.29M
6.1%
-61.73K
-1.84%
Mar 31, 2025
Logos Global Management LP
2.95M
5.48%
+2.95M
--
May 29, 2025
Armistice Capital LLC
2.20M
4.08%
-40.00K
-1.79%
Mar 31, 2025
Palo Alto Investors LP
1.66M
3.08%
-78.23K
-4.50%
Mar 31, 2025
State Street Global Advisors (US)
1.52M
2.83%
-340.28K
-18.28%
Mar 31, 2025
Invus Public Equities Advisors, LLC
1.28M
2.38%
+183.72K
+16.70%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
1.08%
iShares Neuroscience and Healthcare ETF
0.63%
Invesco NASDAQ Future Gen 200 ETF
0.6%
Tema Neuroscience and Mental Health ETF
0.3%
Federated Hermes MDT Small Cap Core ETF
0.3%
ALPS Medical Breakthroughs ETF
0.22%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares ESG Aware MSCI USA Small-Cap ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.03%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比1.08%
iShares Neuroscience and Healthcare ETF
佔比0.63%
Invesco NASDAQ Future Gen 200 ETF
佔比0.6%
Tema Neuroscience and Mental Health ETF
佔比0.3%
Federated Hermes MDT Small Cap Core ETF
佔比0.3%
ALPS Medical Breakthroughs ETF
佔比0.22%
Invesco Nasdaq Biotechnology ETF
佔比0.04%
iShares ESG Aware MSCI USA Small-Cap ETF
佔比0.04%
ProShares Ultra Nasdaq Biotechnology
佔比0.04%
iShares Biotechnology ETF
佔比0.03%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
